CTC
BPMC

Central Trust Company’s Blueprint Medicines BPMC Stock Holding History

Central Trust Company’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23
Closed -$2.95K – 1423
2025
Q2 		$2.95K Hold
23
– – ﹤0.01% 1274
2025
Q1 		$2.04K Hold
23
– – ﹤0.01% 1316
2024
Q4 		$2.01K Hold
23
– – ﹤0.01% 1321
2024
Q3 		$2.13K Hold
23
– – ﹤0.01% 1256
2024
Q2 		$2.48K Hold
23
– – ﹤0.01% 1258
2024
Q1 		$2.18K Hold
23
– – ﹤0.01% 1268
2023
Q4 		$2.12K Hold
23
– – ﹤0.01% 1280
2023
Q3 		$1.16K Buy
+23
New +$1.23K ﹤0.01% 1300
2022
Q3 		– Sell
-6
Closed – – 1305
2022
Q2 		$0 Hold
6
– – ﹤0.01% 1367
2022
Q1 		$0 Sell
6
-144
-96% -$10.3K ﹤0.01% 1354
2021
Q4 		$16K Hold
150
– – ﹤0.01% 978
2021
Q3 		$15K Hold
150
– – ﹤0.01% 965
2021
Q2 		$13K Buy
150
+100
+200% +$9.16K ﹤0.01% 969
2021
Q1 		$5K Buy
50
+20
+67% +$2K ﹤0.01% 1001
2020
Q4 		$3K Sell
30
-20
-40% -$2.11K ﹤0.01% 1017
2020
Q3 		$5K Hold
50
– – ﹤0.01% 931
2020
Q2 		$4K Buy
+50
New +$3.38K ﹤0.01% 949

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Central Trust Company's BPMC Position: Q3 2025 in Review

Central Trust Company sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 23 shares — an estimated $2.95K sold.

Central Trust Company first reported a position in BPMC in Q2 2020 and held it in 17 quarters. The position peaked at $16K in Q4 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Central Trust Company reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Central Trust Company sold 23 Blueprint Medicines shares in Q3 2025, an estimated $2.95K.
  • Central Trust Company first reported a position in Blueprint Medicines in Q2 2020 and held it in 17 quarters.
  • Central Trust Company's Blueprint Medicines position peaked at $16K in Q4 2021.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Central Trust Company's 13F filing for Q3 2025, filed 6 Nov 2025.